Use in subjects with moderate (1–5%) or mild haemophilia A (6–40%) as a prophylactic treatment was questioned because of the extended half-life of 40 h of Altuvoct, which is notably longer than that of currently approved FVIII medicinal products, where the half-life is around 24 h. The gene discussed is F8; the disease is hemophilia A.